Despite having a favourable pharmacokinetic profile and specificity for tau, further study is required in determining the clinical utility of in vivo imaging using [18F]AV‐1451 in AD and MCI (Chien et al., 2014; Zhang et al., 2012). This evidence concerns the gene MAPT and Alzheimer disease.